Peter Blume-Jensen, Acrivon Therapeutics CEO

Acrivon bags a megaround to ad­vance an old Eli Lil­ly pro­gram, 5 months af­ter launch. Is an IPO far be­hind?

Not five months af­ter launch­ing with an old Eli Lil­ly as­set, Acrivon Ther­a­peu­tics is al­ready up­ping the ante.

The Cam­bridge, MA-based biotech pulled in $100 mil­lion in a new Se­ries B, aim­ing to fur­ther ad­vance its lead as­set and com­pan­ion plat­form. And the com­pa­ny has re­cruit­ed some blue-chip back­ers for the raise as RA Cap­i­tal Man­age­ment and Per­cep­tive Ad­vi­sors both par­tic­i­pat­ed in the round.

Does that mean an IPO is on the hori­zon? CEO Pe­ter Blume-Jensen won’t rule it out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.